The incidence of new cases of CRC in Poland for the year 2013 were 1,900 new CRC cases with 545 cancers in men and 1,335 new cases of CRCs with 359 in women in Poland. However, 5.5% of the new CRC cases were due to adenomatous polyps. Only 19·3% had invasive colorectal cancers. The average age of CRC patients was 65.6 years. In men the average age of new primary CRC cases was 63 years old while in women it was 61·7 years old.
The incidence of [colo[rectal cancer](https://www.withpower.com/clinical-trials/rectal-cancer)](https://www.withpower.com/clinical-trials/colorectal-cancer) in the US dramatically increased between 1991 and 1999 by 18%, leading to a more than 30% increase in colorectal cancer incidence between 1993 and 2002 in the US. The increase was more pronounced in men than in women. Although the increase was driven primarily by colon cancer, the increase occurred in rectum cancer as well. The increase was particularly evident among colon and rectal cancer in Hispanics and White, black, and Hispanic men. Colorectal cancer was one of the top 10 most common causes of cancer death in the US in 2012.
In the past decades, numerous agents have been developed for treatment of colorectal cancer and various novel agents are still in the development stage. However, the effectiveness of chemotherapy agents for colorectal cancer remains limited, and the development of more potent chemotherapeutic drugs is still needed. Chemotherapeutic agents commonly used for colorectal cancer include fluorouracil, 5-fluorouracil, cisplatin, irinotecan, docetaxel, capecitabine and oxaliplatin.
A combination of environmental and genetic factors influence CRC occurrence. For CRC, the primary risk factors are age at diagnosis and male sex, whereas smoking is an important modifiable factor.
Around 16,100 people die of [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) per year, making it the third most frequent cause of cancer-related death in the US. Approximately 50% of colorectal cancers are diagnosed at an early stage. These data strongly support the need to increase the rate of colonoscopy in the US population, as an important tool in the discovery of colorectal cancer.
It is important for patients to recognize their initial symptoms before medical treatment. Among these, rectal bleeding and anemia are the most common, but abdominal pain, swelling or a palpable mass are more subtle. All of these signs are associated with colorectal cancer.
A PET-derived target dose of up to 25 mCi (80 megavolume) given as a repeated sigmoidoscopy scan per week is well tolerated both with and without (131)I.
Clinical research activities are expanding to address many facets of cancer care, and colorectal cancer constitutes another area in which significant progress is needed. Therefore, we believe that patients and clinicians should be informed about potential limitations and the implications of clinical research.
[89zr]Panitumumab PET was found to be technically feasible with a short, low-molecular-weight peptide, and it could be a helpful tool for evaluating the tumour response to [89zr]panitumumab PET-mri in colorectal cancer.
This illustrates that most people spread colorectal cancer within 2 years. This data may help develop the tools of prevention. A good prevention option will be a screening for colorectal cancer every one to three years, or more regularly until the patient is 75.
The survival rate for colorectal cancer is approximately 68% and depends on the stage. Overall, the 5-year and 10-year survival rates are 52% and 45%, respectively. Survival rate is lower for patients presenting with a nodal or lymph node metastasis. The 5-year survival rates for patients with stage IV colorectal cancer are 25%, compared to 80% for stage II colorectal cancer. The 5-year mortality rate for stage I colorectal cancer is about 13%, and nearly 80% of patients survive beyond 10 years.
Results from a recent clinical trial suggest that [(89)Zr]panitumumab PET-MRI may offer a promising method to provide non-invasive imaging of tumor response to pembrolizumab treatment. ClinicalTrials.gov: NCT00881345.